Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Endoglin-mediated suppression of prostate cancer invasion is regulated by activin and bone morphogenetic protein type II receptors.

Breen MJ, Moran DM, Liu W, Huang X, Vary CP, Bergan RC.

PLoS One. 2013 Aug 13;8(8):e72407. doi: 10.1371/journal.pone.0072407. eCollection 2013.

2.

Endoglin suppresses human prostate cancer metastasis.

Lakshman M, Huang X, Ananthanarayanan V, Jovanovic B, Liu Y, Craft CS, Romero D, Vary CP, Bergan RC.

Clin Exp Metastasis. 2011 Jan;28(1):39-53. doi: 10.1007/s10585-010-9356-6. Epub 2010 Oct 28.

3.

Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway.

Craft CS, Romero D, Vary CP, Bergan RC.

Oncogene. 2007 Nov 8;26(51):7240-50. Epub 2007 May 14.

4.

Rapid Activation of Bone Morphogenic Protein 9 by Receptor-mediated Displacement of Pro-domains.

Kienast Y, Jucknischke U, Scheiblich S, Thier M, de Wouters M, Haas A, Lehmann C, Brand V, Bernicke D, Honold K, Lorenz S.

J Biol Chem. 2016 Feb 12;291(7):3395-410. doi: 10.1074/jbc.M115.680009. Epub 2015 Dec 16.

5.
6.

Genistein induces phenotypic reversion of endoglin deficiency in human prostate cancer cells.

Craft CS, Xu L, Romero D, Vary CP, Bergan RC.

Mol Pharmacol. 2008 Jan;73(1):235-42. Epub 2007 Oct 19.

7.

BMP and TGFbeta pathways in human central chondrosarcoma: enhanced endoglin and Smad 1 signaling in high grade tumors.

Boeuf S, Bovée JV, Lehner B, van den Akker B, van Ruler M, Cleton-Jansen AM, Richter W.

BMC Cancer. 2012 Oct 22;12:488. doi: 10.1186/1471-2407-12-488.

8.

Transforming Growth Factor-β Family Ligands Can Function as Antagonists by Competing for Type II Receptor Binding.

Aykul S, Martinez-Hackert E.

J Biol Chem. 2016 May 13;291(20):10792-804. doi: 10.1074/jbc.M115.713487. Epub 2016 Mar 9.

9.

Bone morphogenetic proteins.

Chen D, Zhao M, Mundy GR.

Growth Factors. 2004 Dec;22(4):233-41. Review.

PMID:
15621726
10.

Activins bind and signal via bone morphogenetic protein receptor type II (BMPR2) in immortalized gonadotrope-like cells.

Rejon CA, Hancock MA, Li YN, Thompson TB, Hébert TE, Bernard DJ.

Cell Signal. 2013 Dec;25(12):2717-26. doi: 10.1016/j.cellsig.2013.09.002. Epub 2013 Sep 7.

PMID:
24018044
11.

BMP signaling pathways affect differently migration and invasion of esophageal squamous cancer cells.

Hu M, Cui F, Liu F, Wang J, Wei X, Li Y.

Int J Oncol. 2017 Jan;50(1):193-202. doi: 10.3892/ijo.2016.3802. Epub 2016 Dec 12.

PMID:
27959431
12.

Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells.

David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S.

Blood. 2007 Mar 1;109(5):1953-61. Epub 2006 Oct 26.

13.

Endoglin mediates fibronectin/α5β1 integrin and TGF-β pathway crosstalk in endothelial cells.

Tian H, Mythreye K, Golzio C, Katsanis N, Blobe GC.

EMBO J. 2012 Oct 3;31(19):3885-900. doi: 10.1038/emboj.2012.246. Epub 2012 Aug 31.

14.

Endoglin promotes TGF-β/Smad1 signaling in scleroderma fibroblasts.

Morris E, Chrobak I, Bujor A, Hant F, Mummery C, Ten Dijke P, Trojanowska M.

J Cell Physiol. 2011 Dec;226(12):3340-8. doi: 10.1002/jcp.22690.

15.

Endoglin phosphorylation by ALK2 contributes to the regulation of prostate cancer cell migration.

Romero D, Terzic A, Conley BA, Craft CS, Jovanovic B, Bergan RC, Vary CP.

Carcinogenesis. 2010 Mar;31(3):359-66. doi: 10.1093/carcin/bgp217. Epub 2009 Sep 7.

16.

Repulsive guidance molecule RGMa alters utilization of bone morphogenetic protein (BMP) type II receptors by BMP2 and BMP4.

Xia Y, Yu PB, Sidis Y, Beppu H, Bloch KD, Schneyer AL, Lin HY.

J Biol Chem. 2007 Jun 22;282(25):18129-40. Epub 2007 May 1.

17.

Endoglin differentially modulates antagonistic transforming growth factor-beta1 and BMP-7 signaling.

Scherner O, Meurer SK, Tihaa L, Gressner AM, Weiskirchen R.

J Biol Chem. 2007 May 11;282(19):13934-43. Epub 2007 Mar 21.

18.

Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2.

Macías-Silva M, Hoodless PA, Tang SJ, Buchwald M, Wrana JL.

J Biol Chem. 1998 Oct 2;273(40):25628-36.

19.

Constitutively active ALK2 receptor mutants require type II receptor cooperation.

Bagarova J, Vonner AJ, Armstrong KA, Börgermann J, Lai CS, Deng DY, Beppu H, Alfano I, Filippakopoulos P, Morrell NW, Bullock AN, Knaus P, Mishina Y, Yu PB.

Mol Cell Biol. 2013 Jun;33(12):2413-24. doi: 10.1128/MCB.01595-12. Epub 2013 Apr 9.

Supplemental Content

Support Center